

Bactiguard[®]

SEB Healthcare Seminar

Wednesday November 22, 2023




Thomas von Koch, CEO





The dangers of biofilm

Medical devices that stay in the body more than two days – a possible danger for infection





BactiGuard



Advanced infection prevention technology that
protects you and reduces the risk of infection.






Opportunities behind critical global healthcare trends

“not a question of if, it’s a question of when”

The issues

- **Antimicrobial resistance** one of the top global public health threats facing humanity – associated with the **death of close to 5 million people globally in 2019**
- **1 in 10 patients** worldwide affected by **healthcare associated infections**
- **Demographic development, ageing population** and increasing **lifestyle diseases**
- Strained **healthcare resources**

The USD 80bn market opportunity



Markets size USD billion



The new, license focused Bactiguard

Purpose (why we exist)


“to champion a **healthier world** by **preventing infections**”

Vision (what we strive to be, visionary, long-term aspiration)

“to be the **global standard of care** for **preventing medical device related infections**”

Mission (what we do to reach our vision)

“by being the **premier partner for leading medtech companies**, joining forces to **redefine healthcare** and **improve health** worldwide”





Biggest strategic shift in Bactiguard's history

Key priorities ahead

License

- strengthen organization
 - double down on current partnerships
 - new partnerships

R&D and coating development

- institutionalize
- Billy Södervall Academy


BIP portfolio

- outsourcing discussions
- orderly transition and gradual phase out

“from a medical device production company to a **knowledge and specialist organization** – and a **profitable high-margin business**”



A license focused business model





Zimmer Biomet Bactiguard EMEA launch

YOU WOULDN'T DRIVE A CAR WITHOUT A SEATBELT

SO WHY TAKE RISKS WITH INFECTION CONTROL?

Zimmer® Natural Nail® (ZNN) System
with **Bactiguard® Technology**

ZIMMER BIOMET



A novel noble metal stent coating reduces in vitro platelet activation and acute in vivo thrombosis formation

Published in Scientific Reports in October 2023 – available on www.bactiguard.com

Joint study by Bactiguard, KI and KTH

- **Efficacy of the coating to reduce thrombo-inflammatory reactions and acute stent thrombosis** – gather more data and to provide proof of concept
- **Two versions of the coating** – “standard” (gold, silver, palladium), and modified version (with neodymium)
- **In vivo** and **in vitro** (pigs and through blood marker analysis, including human samples)
- **Coated stent group significant decrease in blood clot volume** vs control group – **effect observed one hour** after the stent was implanted, more accentuated after two hours
- **Conclusion:** promising results, Bactiguard’s coating has the **potential to reduce the thrombo-inflammatory reaction of an intravascular device**

Bactiguard[®]



**Karolinska
Institutet**





Why invest in Bactigard?

A recap of today's presentation

- AMR caused the death of close to **5 million people** globally in 2019 – a **silent tsunami**
- **Biofilm on a medical device** the start of a potential infection
- **Medical devices in the body more than two days should be coated** – value of uncoated medical devices sold today around USD 100bn
- **Antibacterial, biocompatible, user-friendly and safe**
- **Prevents infection** – to repel instead of kill bacteria
- **License focused strategy** – major market potential behind **critical global healthcare trends**





Q&A

“to champion a healthier world
by preventing infections